AN UNUSUAL PRESENTATION OF STEVEN-JOHNSON SYNDROME AFTER BNT162B2 COVID-19 VACCINATION

Authors

  • Ravi Patel Department of trauma and orthopaedics, Grimsby
  • Victor Lu Department of Trauma and Orthopaedics, Addenbrooke’s Hospital, CB2 0QQ, United Kingdom

DOI:

https://doi.org/10.55519/JAMC-01-11097

Keywords:

Adverse drug reaction, Pharmacology, Medical Education, General Medicine

Abstract

We present a 23-year-old white British male that presented to the Accident and Emergency Department, two weeks after the second dose of the BNT162b2 (BioNTech/Pfizer) vaccine. No similar use has been documented previously in literature. We report one potential complication of the Pfizer COVID-19 vaccine: a known case of Stevens-Johnson syndrome (SJS) that occurred after the second dose of the Pfizer COVID-19 vaccine alone without exposure to any other drug. Despite a significantly severe adverse drug reaction, the patient demonstrated completed recovery. The risk of developing severe cutaneous drug reaction from subsequent COVID-19 vaccinations in these patients is still unclear and remains a dilemma to date.

References

McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol 2021;85(1):46–55.

Tong J, Chan J. Stevens-Johnson Syndrome Due to Influenza Vaccination. Cureus 2020;12(7):e9405.

Padniewski JJ, Jacobson-Dunlop E, Albadri S, Hylwa S. Stevens–Johnson syndrome precipitated by Moderna Inc. COVID-19 vaccine: a case-based review of literature comparing vaccine and drug-induced Stevens–Johnson syndrome/toxic epidermal necrolysis. Int J Dermatol 2022;61(8):923–9.

Kong J, Cuevas-Castillo F, Nassar M, Lei CM, Idrees Z, Fix WC, et al. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report. J Infect Public Health 2021;14(10):1392–4.

Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010;5:39.

Published

2023-01-02

Issue

Vol. 35 No. 1 (2023): JOURNAL OF AYUB MEDICAL COLLEGE ABBOTTABAD

Section

CASE REPORT

License

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.